| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD40 |
| Uniprot No | Q13114 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-193aa |
| 氨基酸序列 | EPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCGESEFLDT WNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCV LHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETK DLVVQQAGTNKTDVVCGPQDRLR |
| 分子量 | 45 kDa |
| 蛋白标签 | Fc tag C-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人CD40蛋白的模拟参考文献示例(实际文献需通过学术数据库查询)：
1. **文献名称**：Structural and functional characterization of recombinant human CD40 ligand protein
**作者**：van Dijk, H. H., et al.
**摘要**：研究通过重组表达技术生产功能性人CD40蛋白，解析其与CD40L结合的晶体结构，并验证其在体外实验中激活B细胞免疫应答的能力。
2. **文献名称**：CD40 agonist antibodies in cancer immunotherapy: Mechanisms and clinical potential
**作者**：Garcia, C. P., et al.
**摘要**：探讨重组CD40蛋白与其激动型抗体在肿瘤免疫治疗中的作用，通过临床前模型证明其增强T细胞抗肿瘤活性及联合用药的治疗潜力。
3. **文献名称**：Recombinant CD40 protein as a vaccine adjuvant for dendritic cell activation
**作者**：Smith, A. L., et al.
**摘要**：评估重组人CD40蛋白作为疫苗佐剂对树突状细胞成熟的调控作用，证明其可提高抗原递呈效率并增强小鼠模型中疫苗的保护效果。
4. **文献名称**：Role of soluble CD40 in autoimmune disease: Insights from recombinant protein studies
**作者**：Müller, J., et al.
**摘要**：利用重组可溶性CD40蛋白研究其在自身免疫性疾病中的调节功能，发现其通过竞争性抑制CD40-CD40L相互作用缓解小鼠类风湿性关节炎症状。
(注：以上为模拟生成的文献示例，具体文献需查阅PubMed、ScienceDirect等平台。)
CD40. a member of the tumor necrosis factor receptor (TNFR) superfamily, is a cell surface protein primarily expressed on antigen-presenting cells (APCs) such as dendritic cells, B cells, and macrophages. It plays a pivotal role in adaptive immunity by interacting with its ligand, CD40L (CD154), on activated T cells. This interaction triggers bidirectional signaling, critical for T-cell priming, B-cell activation, antibody class switching, and germinal center formation. Dysregulation of CD40-CD40L signaling is linked to autoimmune diseases, cancer, and immunodeficiency disorders.
Recombinant human CD40 protein, produced via mammalian or bacterial expression systems, is engineered to mimic native CD40 activity. It often includes functional domains like the extracellular region for ligand binding and may incorporate Fc fusion tags to enhance stability and solubility. Researchers utilize this protein in vitro and in vivo to study immune modulation, receptor-ligand interactions, and therapeutic targeting. In oncology, CD40 agonists are explored to activate APCs, promoting antitumor immune responses. Conversely, CD40-blocking agents are investigated for treating autoimmune conditions.
Recent advances highlight its dual role as an immune checkpoint regulator, driving interest in CD40-targeted biologics. Its therapeutic potential, combined with evolving structural insights, positions recombinant CD40 protein as a key tool in immunology research and drug development.
×
